The appointment in brief

A ChondroFiller hip injection at Lincolnshire Hip is an outpatient appointment, not an operation. There is no theatre admission, no overnight stay, and no general or spinal anaesthetic — only a local anaesthetic to numb the skin and soft tissue around the hip before the needle is placed.

The appointment runs for roughly 30 to 45 minutes in total. It is available at two clinic sites: Grantham and Sleaford. The cost is £2,995 per injection, which covers the full procedural package — including the pre-injection ultrasound scan, the ChondroFiller product itself, the guided injection, and a six-week follow-up appointment.

The appointment is longer than a standard joint injection because real-time ultrasound imaging is used throughout — a step that takes time but is clinically necessary at the hip, as the following section explains.

Why the hip joint needs ultrasound guidance

The hip joint sits considerably deeper in the body than most other injectable joints. At the anterior recess — the target site, positioned where the femoral head meets the neck — the needle must travel between 3.5 and 7 centimetres below the skin surface, a depth that varies with each patient's build and cannot be judged reliably from surface landmarks alone.

Running immediately alongside that needle corridor are three critical structures: the femoral nerve, the femoral artery, and the circumflex vessels. Their exact positions shift with body shape and cannot be predicted from a standard anatomical map. Before any needle is advanced, a colour Doppler pre-scan is performed specifically to trace these structures in real time and confirm a safe approach for that individual patient. This is a routine step, not an emergency precaution — it simply ensures the plan is tailored rather than assumed.

The published evidence for using ultrasound at this site is clear. A meta-analysis of 75 studies, summarised in a 2023 PMC narrative review, found that ultrasound-guided hip injection achieves 90–96% placement accuracy compared with 70–80% for a blind landmark technique — an odds ratio of 5.18 in favour of ultrasound guidance (p<0.001).

For ChondroFiller specifically, placement precision carries an additional mechanical rationale. Once the collagen matrix is injected, it begins to self-gel within approximately three to five minutes. Gel that sets outside the joint space cannot fulfil its purpose as a cartilage scaffold, so delivery directly into the hip joint — confirmed under live imaging — is not simply best practice: it is a prerequisite for the treatment to work.

What ChondroFiller is and how it gels in the hip joint

Unlike a corticosteroid or hyaluronic acid injection — which act on symptoms once dispersed through the joint — ChondroFiller is a medical device rather than a drug or lubricant, designed to remain in place as a structural foundation for tissue repair.

The device arrives in a ready-to-use two-chamber syringe: one chamber holds an acid-extracted Type I collagen solution, the other a neutralising solution. As the clinician depresses the plunger, the two components pass through a mixing adapter and combine at the point of delivery. Inside the hip joint, the mixed material transforms from a viscous liquid into a dimensionally stable hydrogel — adapting to the shape of the cartilage defect as it sets within the three-to-five-minute window described above.

That scaffold then acts through acellular matrix-induced chondrogenesis — in plain terms, the collagen structure draws the patient's own progenitor cells, migrating in from the surrounding synovium and subchondral bone, into the matrix. There they begin remodelling it into fibrocartilage-like repair tissue over the months that follow. The device itself gradually dissolves, leaving new tissue where there was previously a defect.

No bone drilling, microfracture, fibrin glue, or cell harvesting is required at any stage. ChondroFiller is CE-marked as a Class III medical device, contains no living cells, and no hyaluronic acid.

Step by step through the injection itself

On arrival at the treatment room, most patients lie on their back on the couch, with the affected hip accessible from the front. Your clinician will confirm the exact position with you beforehand, as the approach may be adjusted slightly depending on individual build and anatomy.

The skin over the front of the hip is cleaned and a small volume of local anaesthetic is injected at the planned needle entry point, numbing the skin and the immediate subcutaneous layer. The brief sting of the anaesthetic is typically the most uncomfortable moment of the entire appointment.

With the local anaesthetic taking effect, the clinician performs the colour Doppler pre-scan already described — quickly confirming the position of the femoral artery, nerve, and circumflex vessels for that individual before any needle is advanced. Live B-mode ultrasound then guides the needle forward to the anterior recess at the front of the hip joint, with placement confirmed on screen.

Once the needle tip is in position, the ChondroFiller syringe is connected and the mixed collagen material is delivered directly into the joint space. You will be asked to remain still at this point. The in-situ gelling process takes roughly three to five minutes to complete; keeping the hip at rest during that window allows the scaffold to stabilise where it has been placed.

When the setting time has elapsed, the needle is withdrawn, pressure is applied to the entry point to minimise bruising, and a sterile dressing is placed over the site. The clinical part of the appointment is then complete.

Leaving the clinic: the first few days

Before you leave the treatment room, a sterile dressing is applied over the entry point and discharge paperwork is prepared. There is no theatre recovery, no ward admission, and no overnight stay — most patients are ready to leave within a few minutes of the procedure finishing.

A discharge letter accompanies you home, setting out the post-procedure care plan and confirming the six-week follow-up appointment that is already part of the pathway.

For the first 24 to 48 hours, the hip should be rested; avoid anything that puts unprotected load through the joint — prolonged standing, stairs taken at pace, or exercise. Some localised aching or mild swelling over the injection site in the day or two afterwards is normal and does not indicate that anything has gone wrong; it reflects the body beginning to respond to the scaffold.

NSAIDs such as ibuprofen are commonly recommended for approximately seven days to settle post-injection soreness and reduce the risk of local inflammation — confirm the specific regimen with your prescribing clinician, particularly if you take other medication.

If you notice increasing warmth or swelling beyond the first 48 hours, any signs of infection at the dressing site, or unusual pain, contact the clinic directly. These calls are uncommon, but the team expects them and the discharge letter will include the relevant contact number.

The repair timeline: what happens over the following months

Recovery after a ChondroFiller hip injection unfolds in three broad phases, each with a different role in the repair process.

Weeks 1–6: protected loading

The first six weeks are a consolidation period. The collagen scaffold has set in place, but the progenitor cells the matrix is designed to recruit are only beginning to migrate in and attach. Reduced-impact activity during this window allows that process to proceed without mechanical disruption. Most patients can walk at a normal pace and manage everyday tasks; the aim is simply to avoid sustained load through the joint — prolonged standing, heavy exercise, or anything that reproduces significant hip pain.

Months 3–6: early tissue repair

From around three months onward, the recruited cells start remodelling the collagen matrix into fibrocartilage-like repair tissue. Many patients begin to notice genuine improvement in pain and function within this window, though the pace varies considerably between individuals.

Months 6–24: progressive maturation

Full tissue remodelling may continue for up to 24 months. Published data suggest around 70–85% of patients achieve meaningful pain relief and improved function, and the hip-specific mHHS outcome benchmark from the arthroscopic literature shows improvement of roughly 30 points — though durability data specific to the ultrasound-guided injection route are still emerging. Results are not uniform; candidacy, defect size, and activity compliance all influence outcomes.

Lincolnshire Hip accepts patients without referral for assessment at Grantham or Sleaford. A clinical review and open MRI are the starting point for establishing whether a ChondroFiller pathway is appropriate for a given patient.